Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Genomics Splits Business into Drug Discovery, Service Units

NEW YORK, Sept. 22 (GenomeWeb News) - Galapagos Genomics has split its business into a drug discovery and a research service unit, the Mechelen, Belgium-based company said today.

 

The service unit will operate under the name Galadeno from the company's facility in Leiden. It will offer both individual adenovirus-based siRNA and full-length gene reagents for drug target discovery and validation. Galadeno will also provide access to its cDNA collection FlexSelect and its siRNA collection SilenceSelect, and will continue to offer a human primary cell-based functional screening platform to partners.

 

The drug discovery business will continue to operate under the name Galapagos and will be located at the company's Mechelen facility.

 

"[T]his separation will allow each unit to grow in a dedicated way," said Galapagos CEO Onno van de Stolpe in a statement.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.